VOLPARA HEALTH TECHNOLOGIES LIMITED (VHT)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

VHT - VOLPARA HEALTH TECHNOLOGIES LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: March
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.28
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.79

05 Dec
2023

0.010

OPEN

$0.75

1.28%

HIGH

$0.79

115,610

LOW

$0.75

TARGET
$1.01 27.8% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CYC . EBR . EMV . EYE . FPH . HLA . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI . VTI .
FNARENA'S MARKET CONSENSUS FORECASTS
VHT: 1
Title FY24
Forecast		 FY25
Forecast
EPS (cps) - 2.0 xxx
DPS (cps) 0.0 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio N/A xxx
Dividend Yield 0.0% xxx
Div Pay Ratio(%) N/A xxx
This company reports in NZD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx-3.5
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx31.9 M
Book Value Per Share xxxxxxxxxxxxxxx18.8
Net Operating Cash Flow xxxxxxxxxxxxxxx-3.5 M
Net Profit Margin xxxxxxxxxxxxxxx-27.99 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx-17.60 %
Return on Invested Capital xxxxxxxxxxxxxxx-17.06 %
Return on Assets xxxxxxxxxxxxxxx-11.99 %
Return on Equity xxxxxxxxxxxxxxx-17.60 %
Return on Total Capital xxxxxxxxxxxxxxx-22.36 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-3.5 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx1 M
Total Debt xxxxxxxxxxxxxxx2 M
Goodwill - Gross xxxxxxxxxxxxxxx20 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx12 M
Price To Book Value xxxxxxxxxxxxxxx4.03

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx2.3 M
Capex % of Sales xxxxxxxxxxxxxxx7.34 %
Cost of Goods Sold xxxxxxxxxxxxxxx7 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx36 M
Research & Development xxxxxxxxxxxxxxx16 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

22/11/2023

1

Buy

$0.85

7.59%

Volpara Health Technologies' September half revenue outpaced consensus (despite being half that of the previous September half) but earnings proved a small miss, observes Bell Potter.

FY24 revenue guidance was maintained. The company closed the half with $13.2m in cash.

Bell Potter observes the company has recorded four consecutive quarters of positive cash flows from operations and, while free cash remains close to zero, it is a massive improvement on the -$7.7m in the previous September half, says the broker.

The broker expects a sharp uplift in cash flow in FY25 and FY26 but downgrades revenue forecasts for those years observing many acquisition clients have not upgraded to the Volpara suite, suggesting its use is yet to go mainstream from academia.

Buy rating retained. Target price falls to 85c from $1.20.

FORECAST
Bell Potter forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -2.13 cents.
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -1.11 cents.
Access Stockbroker Research History >

VHT STOCK CHART

FNArena News on VHT

1
FNArena Corporate Results Monitor – 29-05-2023

May 29 2023 - Australia
2
Australian Broker Call *Extra* Edition – Jan 25, 2023

Jan 25 2023 - Daily Market Reports
3
In Brief: Lithium, Telcos, SMAs, Healthcare

Dec 23 2022 - Weekly Reports
4
Australian Broker Call *Extra* Edition – Nov 09, 2022

Nov 09 2022 - Daily Market Reports
5
Rudi’s View: Minus 20%

Jul 07 2022 - Rudi's View

Latest Medical Equipment & Devices News

1
Dr Boreham’s Crucible: Pro Medicus

Oct 23 2023 - Australia
2
Dr Boreham’s Crucible: Cyclopharm

Oct 09 2023 - Small Caps
3
Dr Boreham’s Crucible: Painchek

Sep 11 2023 - Small Caps
4
Margins Signal Integral Diagnostics Recovery

Sep 07 2023 - Australia
5
ResMed: Finding A Base?

Aug 15 2023 - Technicals
6
August Turns ResMed Into Nigel NoMates

Aug 09 2023 - Australia
7
Dr Boreham’s Crucible: Lumos Diagnostics

Jun 19 2023 - Small Caps
8
Fisher & Paykel Healthcare: Lower Margin, Higher Spending

May 30 2023 - Australia
9
Dr Boreham’s Crucible: Impedimed

May 08 2023 - Small Caps
10
Treasure Chest: ResMed’s Benevolent Monopoly

May 01 2023 - Treasure Chest